| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2003; 42: 321-325
© 2003 British Society for Rheumatology
Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout
Lipid Clinic and
1 Department of Rheumatology, Chelsea and Westminster Hospital, London SW10 9NH, UK
Objective. To assess the short-term urate-lowering effect of fenofibrate in men on long-term allopurinol therapy for hyperuricaemia and gout.
Methods. Ten male patients (38–74 yr) with a history of chronic tophaceous or recurrent acute gout with hyperuricaemia and on established allopurinol at 300–900 mg/day for 
3 months were studied in an open-crossover study of fenofibrate therapy. Allopurinol at the established dose was continued throughout the study. Clinical and biochemical assessments (serum urate and creatinine, 24-h urinary excretion of urate and creatinine, liver function tests, creatine kinase and fasting serum lipids) were undertaken at: (i) baseline, (ii) after 3 weeks of once-daily therapy with micronized fenofibrate (Lipantil Micro®) at 200 mg and (iii) 3 weeks after fenofibrate was withdrawn.
Results. Fenofibrate was associated with a 19% reduction in serum urate after 3 weeks of treatment (mean±S.E. 0.37±0.04 vs 0.30±0.02 mM/l; P=0.004). The effect was reversed after a 3-week fenofibrate withdrawal period (0.30±0.02 vs 0.38±0.03 mM/l). There was a rise in uric acid clearance with fenofibrate treatment of 36% (7.2±0.9 vs 11.4±1.6 ml/min, normal range 6–11; P=0.006) without a significant change in creatinine clearance. Both total cholesterol and serum triglycerides were also reduced. No patient developed acute gout whilst taking fenofibrate.
Conclusions. Fenofibrate has a rapid and reversible urate-lowering effect in patients with hyperuricaemia and gout on established allopurinol prophylaxis. Fenofibrate may be a potential new treatment for hyperuricaemia and the prevention of gout, particularly in patients with coexisting hyperlipidaemia or those resistant to conventional therapy for hyperuricaemia.
KEY WORDS: Fenofibrate, Allopurinol, Hyperuricaemia, Gout.
Correspondence to: M. D. Feher, Beta Cell Diabetes Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK. E-mail: m.feher{at}chelwest.nhs.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. C. Wall and S. A. Cooper Gout and Hyperuricemia: New Guidelines and Treatments Journal of Pharmacy Practice, February 1, 2009; 22(1): 104 - 115. [Abstract] [PDF]
|
|
|
|
 |
|
 W Zhang, M Doherty, T Bardin, E Pascual, V Barskova, P Conaghan, J Gerster, J Jacobs, B Leeb, F Liote, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis, October 1, 2006; 65(10): 1312 - 1324. [Abstract] [Full Text] [PDF]
|
|